Immune to Cancer: The CRI Blog
-
Immune Checkpoint Inhibitors: What’s Next?
What’s ahead beyond CTLA-4 and PD-1?
-
Phase 3 Trial of Nivolumab Shows Survival Advantage in Lung Cancer
The results of a phase III trial are clear: the PD-1 checkpoint inhibitor nivolumab improves survival for…
-
New Cancer Immunotherapy Opdivo Approved by FDA
Just hours ago, the FDA approved Bristol-Myers Squibb's PD-1 drug for melanoma.
-
Immunotherapy for Blood Cancers: What to Look for at the Upcoming ASH Meeting
Look for the latest results from trials of PD-1 inhibitors and new developments in adoptive cell transfer.
-
FDA Approves New Cancer Immunotherapy
Merck's new immunotherapy, Keytruda (pembrolizumab), was approved today by the FDA, making it the first PD-1 inhibitor…
-
Two Immunotherapies Clear Important Regulatory Hurdles
The anti-PD-1 drug nivolumab receives the go-ahead for use in Japan, while in the U.S., CAR-T cells…